Premium
Macrophage apolipoprotein E and proliferation of breast cancer cells MCF‐7: Role of LXR
Author(s) -
Bard JeanMarie,
El Roz Ali,
Valin Sabine,
Huvelin JeanMichel,
Nazih Hassan
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.639.11
Subject(s) - mcf 7 , viability assay , apoptosis , thp1 cell line , microbiology and biotechnology , macrophage , chemistry , cancer cell , cell growth , mtt assay , foam cell , cell culture , cell , apolipoprotein b , in vitro , biology , cancer , cholesterol , biochemistry , human breast , genetics
Objective Apolipoprotein (apo) E is expressed by macrophages under control of LXR, a transcription factor. LXR agonists may inhibit cancer cell proliferation in vitro. We evaluate the effect of apo E, secreted by macrophages under control of LXR on MCF‐7 cell proliferation, a model of breast cancer cells. Methods Macrophages derived from THP‐1 monocytes were incubated with LXR agonists [22(R)‐hydroxycholesterol and TO901317 ] before (THP‐1 + agonists) and after (THP‐1 + siRNA apo E) deprivation of apo E by siRNA. MCF‐7 cells were incubated with media from each macrophage model, as well as exogenous apo E (20 μg/mL). Cell viability was tested by MTT method and apoptosis gene expression (BAX, Bcl‐2) was analysed by qPCR. Results Apo E, as determined by ELISA and qPCR is increased in “THP‐1 + agonsits” medium and decreased in “THP‐1 + siRNA apo E” medium. MCF‐7 cell viability is decreased by 18 % and 40% after 24h and 48h incubation with exogenous apo E. Medium from “THP‐1 + agonists” decreases MCF‐7 cell viability by 30% after 24h incubation, while medium from “THP‐1 + siRNA apo E” has no effect. The pro‐apoptotic gene BAX is overexpressed in MCF‐7 cells treated with medium from “THP‐1 + agonists” and underexpressed when treated with medium from “THP‐1 + siRNA apo E”. Conclusion Apo E from macrophages stimulated by LXR agonists may inhibit cell proliferation and induce apoptosis in MCF‐7, a model of breast cancer cells.